Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Rituximab Followed by R-CHOP in Elderly Untreated DLBCL
NCT04058470Phase 2Recruiting
- Start
- Apr 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), anaplastic large cell lymphoma (ALCL). Started Apr 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT04058470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058470.